BTL Emsella Chair Versus Sham for the Treatment of Fecal Incontinence

Status Withdrawn

Clinical Trial Summary

The purpose of this clinical trial is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of fecal incontinence. Currently there are no other studies utilizing the Emsella Chair for the treatment of fecal incontinence. Eligible subjects will receive 2 treatments per week for a total of 4 weeks.

Clinical Trial Description

Fecal incontinence, no matter how frequent, may significantly affect a patient's quality of life. Current available treatment options include; establishing a bowel regimen that consists of supplements, over the counter medications (stool softeners, laxatives, anti-diarrheal, enemas), or utilizing other prescription drugs (Linzees, Lomotil). Other conservative treatments include biofeedback therapy with a physical therapist. More invasive procedures include the injection of bulking agents or sacral nerve stimulation implantation.

The Emsella chair is currently approved as a treatment for stress urinary incontinence. The Emsella chair generates electromagnetic stimulation which is able to penetrate deep into the pelvic floor muscles inducing stimulation and providing rehabilitation for weak pelvic floor muscles. The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.

Subjects meeting eligibility will be randomized (1:1) to receive treatment with the Emsella chair and dietary counseling or sham Emsella chair with dietary counseling. A total of 8 treatments (2 treatments per week for 4 weeks) will be completed. For treatment delivery, participants will sit on the device and the chair height will be adjusted to ensure the subject's feet are on the floor. The sham Emsella treatment will provide some sensation without active HIFEM technology. ;

Study Design

Related Conditions & MeSH terms

Fecal Incontinence

Clinical Trial Details

NCT number	NCT04138602
Study type	Interventional
Source	William Beaumont Hospitals
Contact
Status	Withdrawn
Phase	N/A
Start date	September 1, 2020
Completion date	September 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03825575` - Sacral Neuromodulation as Treatment for Fecal Incontinence	N/A
Completed	`NCT00605826` - A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence	N/A
Withdrawn	`NCT02208258` - Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.	N/A
Completed	`NCT01939821` - A Pilot Study to Evaluate Educational Programs to Improve Fecal Incontinence Care in Nursing Homes	N/A
Completed	`NCT01957969` - French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence	N/A
Completed	`NCT01710579` - Normal Values in Ano-rectal 3D High Resolution Manometry	N/A
Recruiting	`NCT00530933` - Tibial Nerve Stimulation for Faecal Incontinence	N/A
Completed	`NCT00565136` - Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms	Phase 1/Phase 2
Withdrawn	`NCT00522691` - Efficacy of Sacral Nerve Stimulation Before Definitive Implantation	N/A
Completed	`NCT00677508` - Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling
Completed	`NCT05032534` - Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence	N/A
Completed	`NCT05058326` - Severity of Fecal Incontinence and Manometric Values Using the Anopress® Device in Women
Completed	`NCT03746834` - NASHA/Dx as a Perianal Implant for the Treatment of Persistent Fecal Incontience After Anorectal Malformation	Phase 4
Completed	`NCT00124904` - Biofeedback for Fecal Incontinence	N/A
Completed	`NCT03028636` - LIBERATE - PRO: Eclipse™ System Registry
Completed	`NCT04097288` - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects	Phase 1
Completed	`NCT05621629` - Management of FI After Surgery of ARM
Completed	`NCT04478799` - Transcutaneous Posterior Nerve Stimulation inTreatment of Fecal Incontience	N/A
Completed	`NCT03252951` - Physical Therapy for Anal Incontinence	N/A
Withdrawn	`NCT00307476` - Comparison of Rectal Trumpet and Standard Care	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.